Analyst firms · Piper Sandler · REPL

Piper Sandler REPL price target and rating history

Replimune Group Inc. (REPL) · Health Care

Piper Sandler rates Replimune Group Inc. (REPL) Neutral with a $4 price target, as of its latest action on Apr 10, 2026. It has published 5 rating actions on REPL since November 2021, including 1 upgrade and 2 downgrades. Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Piper Sandler's $4 is 67% below that.

Current rating
Neutral
Price target
$4
Median target, all firms
$12
Actions on REPL
5

Piper Sandler price target on REPL

$52$28$320222023202420252026
Piper Sandler price target on REPL, each point a stated target, November 2021 to April 2026.

Every Piper Sandler rating on REPL

How other firms rate REPL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
WedbushOutperform$12Aug 7, 2026
Leerink PartnersOutperform$17Aug 4, 2026
Cantor FitzgeraldOverweightJul 31, 2026
BMO Capital MarketsOutperform$16Jun 30, 2026
JefferiesHold$2Apr 13, 2026
H.C. WainwrightSellApr 13, 2026
Piper SandlerNeutral$4Apr 10, 2026

Questions about Piper Sandler and REPL

What is Piper Sandler's price target for REPL?
Piper Sandler's latest stated price target for Replimune Group Inc. (REPL) is $4, from its action on Apr 10, 2026.
What is Piper Sandler's rating on REPL?
Piper Sandler rates REPL Neutral, a neutral rating, as of Apr 10, 2026.
When did Piper Sandler last change its view on REPL?
On Apr 10, 2026, Piper Sandler downgrades to Neutral from Overweight, price target $4.
How does Piper Sandler's REPL target compare with other analysts?
Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Piper Sandler's $4 is 67% below that.

More REPL rating histories

All Piper Sandler ratingsREPL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.